Skip to main content

Bipolar Disorders

The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
Psych Congress Steering Committee member Vladimir Maletic, MD, MS, discusses how frequently patients can cycle between depression and mania.
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
The risk for Parkinson disease appears to be much higher in people with bipolar disorder than in the general population, according to a systematic review and meta-analysis.
Back to Top